Autonomic disorders can present with hypotension, gastrointestinal, genitourinary symptoms, and heat intolerance. Diabetes is the most common causes of autonomic failure, and management should focus on glucose control to prevent developing autonomic symptoms. The most prevalent cause of dysautonomia, or autonomic dysfunction, is Postural Orthostatic Tachycardia Syndrome (POTS). Autonomic testing characterizes causes for nonspecific symptoms but is not necessary in patients with classic presentations. Treatment for autonomic dysfunction and failure focus on discontinuing offending medications, behavioral modification, and pharmacologic therapy to decrease symptom severity. Autonomic failure has no cure; therefore, the focus remains on improving quality of life.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pop.2024.02.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A systematic review and meta-analysis investigating the impact of exercise interventions on heart rate variability in hemodialysis patients.
Sci Rep
December 2024
Exercise Assessment and Prescription Laboratory, São Paulo State University (UNESP), São Paulo, Brazil.
Patients with chronic kidney disease have a high incidence of cardiovascular diseases, and autonomic dysfunction has a determinant role in the relevant declines. Physical exercise influences heart rate variability and cardiac autonomic modulation. Thus, our objective was to systematically review, with a meta-analysis, the correlation between physical exercise interventions and alterations in cardiac autonomic modulation in hemodialysis patients.
View Article and Find Full Text PDFHeart rate variability parameters indicate altered autonomic tone in subjects with COVID-19.
Sci Rep
December 2024
Krannert Cardiovascular Research Center, Division of Cardiovascular Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
COVID-19 is associated with long-term cardiovascular complications. Heart Rate Variability (HRV), a measure of sympathetic (SNS) and parasympathetic (PNS) control, has been shown to predict COVID-19 outcomes and correlate with disease progression but a comprehensive analysis that includes demographic influences has been lacking. The objective of this study was to determine the balance between SNS, PNS and heart rhythm regulation in hospitalized COVID-19 patients and compare it with similar measurements in healthy volunteers and individuals with cardiovascular diseases (CVD), while also investigating the effects of age, Body Mass Index (BMI), gender and race.
View Article and Find Full Text PDFClinical Correlates of Efficacy of Pyridostigmine in the Treatment of Orthostatic Hypotension.
Hypertension
December 2024
Vanderbilt Autonomic Dysfunction Center, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN. (L.E.O., A.D., C.A.S., A.G., B.K.B., S.P., I.B.).
Background: The cholinesterase inhibitor pyridostigmine is used to treat orthostatic hypotension by facilitating cholinergic neurotransmission in autonomic ganglia, thereby harnessing residual sympathetic tone to increase blood pressure (BP) preferentially in the upright posture. We hypothesized that less severe autonomic impairment was associated with greater pressor responses to pyridostigmine.
Methods: To identify predictors of pressor response, linear regression analyses between the effect of pyridostigmine on upright BP and markers of autonomic impairment were retrospectively conducted on 38 patients who had a medication trial with pyridostigmine (60 mg single dose).
Heartificial intelligence: smart solutions for CHF: An A(I)MT approach.
J Physiol
December 2024
Department of Anesthesiology, University of Nebraska Medical Center, Omaha, NE, USA.
N-terminus α-synuclein detection reveals new and more diverse aggregate morphologies in multiple system atrophy and Parkinson's disease.
Transl Neurodegener
December 2024
Department of Anatomy and Medical Imaging, University of Auckland, 85 Park Road, Grafton, , Auckland, 1142, New Zealand.
Background: Parkinson's disease (PD) and multiple system atrophy (MSA) are classified as α-synucleinopathies and are primarily differentiated by their clinical phenotypes. Delineating these diseases based on their specific α-synuclein (α-Syn) proteoform pathologies is crucial for accurate antemortem biomarker diagnosis. Newly identified α-Syn pathologies in PD raise questions about whether MSA exhibits a similar diversity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!